Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
15 hedge funds and large institutions have $1.26M invested in Statera Biopharma, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
6% less funds holding
Funds holding: 16 → 15 (-1)
15% less capital invested
Capital invested by funds: $1.49M → $1.26M (-$224K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$38.9K |
| 2 |
Renaissance Technologies
New York
|
+$26.4K |
| 3 |
BlackRock
New York
|
+$7.09K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.25K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$139 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7.12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $662K | +$26.4K | +9,500 | +4% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $419K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $64K | +$38.9K | +13,995 | +117% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $41K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $38K | +$5.25K | +1,888 | +14% |
|
|
6
BlackRock
New York
| $35K | +$7.09K | +2,548 | +22% |
|
|
7
UBS Group
Zurich,
Switzerland
| $3K | -$7.12K | -2,560 | -65% |
|
|
8
Wells Fargo
San Francisco,
California
| – | +$139 | +50 | +33% |
|
STAB Hedge Fund Activity: Q2 2018 in Review
15 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2018, worth a combined $1.26M — down 15% from $1.49M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of STAB and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was Susquehanna International Group, adding an estimated $38.9K. The largest seller was UBS Group, cutting an estimated $7.12K.
- 15 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2018, down from 16 in Q1 2018.
- Funds reported $1.26M of Statera Biopharma, Inc. Common Stock stock for Q2 2018, down 15% quarter-over-quarter.
- 0 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2018 and 1 closed out, a net change of -1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2018 was Susquehanna International Group, an estimated $38.9K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2018 was UBS Group, an estimated $7.12K sold.
Based on aggregated 13F filings for Q2 2018.